I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ISTH 2026

We will be contributing to topics related to
-
11:00 AM
Duration 15mins Paris, France
Major surgeries in people with hemophilia A under NXT007 prophylaxis: experience from NXTAGE Phase I/II study
Nogami K, Ogiwara K, Shimonishi N, Nakajima Y, Osuna M, Mizuno N, Kamei Y, Kobayashi R, Shima M, Chen YC
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Paris, France
NXT007 prophylaxis in people with hemophilia A with or without factor VIII inhibitors: Combined analysis of two Phase I/II multiple-ascending-dose studies
Mancuso ME, Shima M, Staber JM, Chen YC, López-Jaime FJ, Shen MC, Ventriglia G, Takeyama M, Schmitt C, Park YS, Kiialainen A, Mizuno N, Niggli M, Miyake T, Matino D, Saito T, Jiménez-Yuste V, Kobayashi R, Hart D, Nogami K
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:45 AM
Duration 60mins Paris, France
Assessment of the bleeding phenotype normality in people with hemophilia A treated with NXT007 prophylaxis: analysis of all-bleed data comparing with healthy volunteers within the NXTAGE study
Shima M, Miwa T, Kojima K, Iwasaki K, Yoneyama K, Sambe T
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Paris, France
Indirect treatment comparison of emicizumab versus efanesoctocog alfa prophylaxis in pediatric people with severe hemophilia A
Al-Adwan M, Niggli M, Tobaruela G
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Paris, France
Mental and emotional impact of emicizumab treatment in people with hemophilia A: post hoc analysis of the HAVEN 3 and 4 Studies
Skinner MW, Lee L, Lim E, Tzeng E, Gao L, Buckner TW
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Paris, France
Reasons for treatment preference in people with hemophilia A switching from FVIII prophylaxis to emicizumab in the BEYOND ABR study: a detailed analysis
Kruse-Jarres R, Castaman G, Di Minno MND, Stephensen D, Lobet S, Barlera S, Brocchieri C, Jiménez-Yuste V
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:45 AM
Duration 60mins Paris, France
AOZORA: safety and joint health outcomes over 6 years in children with hemophilia A – preliminary report from an early cohort
Shima M, Takedani H, Kitsukawa K, Taki M, Ishiguro A, Nagae C, Nagao A, Ioka A, Hoshiba M, Sugawara Y, Iwasaki K, Nogami K
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon